Stable dosage forms of levomilnacipran

  • US 8,481,598 B2
  • Filed: 01/14/2011
  • Issued: 07/09/2013
  • Est. Priority Date: 11/06/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating major depressive disorder in a patient in need thereof, comprising administering to the patient about 120 mg/day of levomilnacipran or a pharmaceutically acceptable salt thereof in one or more sustained release oral dosage forms,wherein the administering step provides a therapeutic blood plasma level of levomilnacipran or pharmaceutically acceptable salt thereof over approximately a twenty-four hour period to treat major depressive disorder in the patient, andwherein the administering step provides an average maximum plasma concentration (Cmax) between about 50 ng/mL and about 350 ng/mL of levomilnacipran or pharmaceutically acceptable salt thereof, an AUC0-∞

  • between about 1000 ng·

    hr/mL and about 9000 ng·

    hr/mL and a Tmax of at least 3 hours to the patient.

View all claims

    Thank you for your feedback